Over the past 20 years, TRB Chemedica has been involved in research and development on some of the main neurodegenerative diseases and neurological indications
such as Parkinson’s disease, stroke, spinal cord injury and chronic pain. Significant efforts and investments have also been directed towards orphan diseases, such as Huntington’s disease, for which no drugs are currently available to slow down or to stop the lethal progression of the disease. We constantly undertake preclinical and clinical assays to identify new mechanisms of action, new indications and to improve the safety of the therapies.
International seminars and workshops in neuroscience and neurology are organised or sponsored by TRB Chemedica every year to gather experts in the field and define new approaches to study the different aspects of neurodegenerative disorders. Since the early 1990’s, TRB Chemedica has been manufacturing and commercialising GM1, a ganglioside extracted from porcine brains. Several studies have shown the neurotrophic, antineurotoxic, neuroprotective and neurorestorative effect of GM11-3 and one of the main targets of TRB Chemedica is to continue the development of this product to extend its indication and to discover additional modes of action.
- Yanagisawa K. GM1 ganglioside and Alzheimer’s disease. Glycoconj J. 2015;32(3-4):105-12.
- Schneider JS, Gollomp SM, Sendek S, Colcher A, Cambi F, Du W. A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson’s disease patients. J Neurol Sci. 2013;324(1-2):140-8.
- Alpaugh M, Galleguillos D, Forero J, Morales LC, Lackey SW, et al. Disease-modifying effects of ganglioside GM1 in Huntington’s disease models. EMBO Mol Med. 2017;9(11):1537-1557.